Skip to Content

Press Releases

Date Title and Summary Additional Formats
May 28, 2024
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY , May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT  system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characterization solutions.
May 22, 2024
SOUTH SAN FRANCISCO, Calif. , May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June: Jefferies Global Healthcare Conference on June 5 th & 6 th
May 20, 2024
SOUTH SAN FRANCISCO, Calif. , May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 20,
May 08, 2024
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million , gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of
Apr 25, 2024
Company expects   to achieve $45-$50 million in annualized operating expense savings in fiscal 2025 Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif.
Apr 25, 2024
SOUTH SAN FRANCISCO, Calif. , April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market.
Apr 08, 2024
New advancements, including automation, aim to fast-forward spatial biology SOUTH SAN FRANCISCO, Calif. , April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the
Apr 03, 2024
SOUTH SAN FRANCISCO, Calif. , April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with global biopharmaceutical company
Mar 18, 2024
SOUTH SAN FRANCISCO, Calif. , March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock
Feb 28, 2024
Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins Completed merger with SomaLogic, activating strategy to build scaled leader in life sciences tools and services Combined pro forma revenue for